BioSig Technologies, Inc. (OTCQB:BSGM) has signed an agreement to initiate development of its PURE EP^TM high fidelity cardiac electrophysiology (EP) signal acquisition and analysis system with Minnetronix, an award-winning medical technology development and manufacturing firm.
According to Greg Cash, President and Chief Executive Officer of BioSig Technologies:

We are very pleased to begin this relationship with Minnetronix, who has proven to be a leader in taking innovative medical technology through the development process and into manufacturing in a timely manner. It is our goal to help patients through positively impacting the diagnosis and treatment of complex cardiac arrhythmias as soon as we possibly can.

Click here to view the full press release.